摘要一：
The management of type 2 diabetes mellitus (T2DM) has evolved from a glucose-centric approach to a comprehensive strategy focused on long-term organ protection and overall cardiometabolic health. As endocrinologists strive to optimize outcomes beyond HbA1c reduction, therapies that provide multidimensional benefits have become increasingly important in routine clinical practice.
Canagliflozin, a dual SGLT2/SGLT1 inhibitor, offers a distinctive mechanism of action by promoting urinary glucose excretion through SGLT2 inhibition while delaying intestinal glucose absorption via transient SGLT1 inhibition. This dual effect contributes to effective glycemic control, reductions in postprandial glucose excursions, and sustained improvements in metabolic parameters. In addition, canagliflozin has demonstrated favorable effects on body weight, blood pressure, and insulin resistance, addressing several key components of the cardiometabolic syndrome commonly associated with T2DM.
Beyond metabolic control, robust clinical evidence supports the role of canagliflozin in reducing the risk of cardiovascular events and slowing the progression of chronic kidney disease. These cardiorenal benefits have reshaped treatment paradigms, positioning SGLT inhibitors as foundational therapies for appropriate patients with T2DM, particularly those at elevated cardiovascular or renal risk.
This presentation will review the comprehensive clinical benefits of dual SGLT inhibition with canagliflozin from an endocrinologist’s perspective. Emphasis will be placed on its unique pharmacological profile, evidence-based cardiorenal protection, and its role in delivering integrated, patient-centered care. By addressing multiple pathophysiological pathways simultaneously, canagliflozin represents an important therapeutic option for improving both short- and long-term outcomes in patients with T2DM.
摘要二：
Diabetes mellitus is increasingly recognized as a systemic disease affecting not only glycemic control but also cardiovascular, renal, and neurological health. From a neurologist’s perspective, the growing burden of cerebrovascular disease, cognitive impairment, and neurovascular complications among patients with type 2 diabetes highlights the need for therapies that provide protection beyond glucose lowering.
Canagliflozin, a dual SGLT2/SGLT1 inhibitor, offers a unique therapeutic approach by targeting multiple pathways involved in diabetes-related organ damage. In addition to improving glycemic control, clinical evidence has demonstrated significant benefits in reducing cardiovascular and renal risks, which are closely linked to neurological outcomes. By lowering blood pressure, reducing body weight, improving metabolic efficiency, and mitigating systemic inflammation,canagliflozin may contribute to a more favorable neurovascular environment.
Emerging data suggest that SGLT inhibition may play a role in reducing the risk of stroke and preserving vascular integrity, particularly in individuals with long-standing diabetes and high cardiovascular risk. Furthermore, the modulation of glucose transport and metabolic pathways may have implications for future strategies aimed at protecting cognitive function and reducing the burden of neurodegenerative disorders.
This presentation will explore the comprehensive benefits of dual SGLT inhibition with canagliflozin, focusing on its potential impact on cardiovascular–renal–metabolic health and the broader neurological implications for patients with type 2 diabetes. By adopting a multidisciplinary perspective, we can better understand how modern diabetes therapies may contribute to improved long-term neurological outcomes and overall patient care.
摘要三：
Type 2 diabetes mellitus is a progressive and multifaceted disease that impacts multiple organ systems, requiring a comprehensive and patient-centered management approach. As family physicians often serve as the first point of contact and long-term care providers, there is an increasing need for treatment strategies that address not only glycemic control but also the broader cardiometabolic risks associated with diabetes.
Canagliflozin, a dual SGLT2/SGLT1 inhibitor, offers benefits extending beyond glucose lowering by targeting several key mechanisms involved in the progression of diabetes-related complications. Through enhanced urinary glucose excretion and delayed intestinal glucose absorption, canagliflozin improves glycemic control while contributing to weight reduction, blood pressure lowering, and metabolic improvement. These effects support the holistic management goals commonly encountered in primary care settings.
In addition to its metabolic benefits, substantial clinical evidence has demonstrated that canagliflozin reduces the risk of cardiovascular and renal events in patients with type 2 diabetes, helping address two of the most important causes of morbidity and mortality in this population. Such organ-protective effects are particularly valuable for family physicians who manage patients with multiple comorbidities and varying levels of cardiovascular and kidney disease risk.
This presentation will review the comprehensive clinical benefits of dual SGLT inhibition with canagliflozin from a primary care perspective. Emphasis will be placed on its role in achieving integrated diabetes management, supporting long-term cardiovascular and renal protection, and improving overall patient outcomes through a simplified and evidence-based therapeutic strategy.
課程說明
※請利用上面連結進行報名，報名完成後，系統將自動發送會議室連結至您填寫的信箱，請至信箱收取，並自行保留準時上課。
(如未收到信件可先確認垃圾郵件及促銷郵件)
請務必詳細閱讀下方說明，報名完成表示同意此課程規範!!
課程注意事項
(1)每堂課程規範不同，請於報名後確認並遵守登錄學分條件。
(2)專業別請填寫正確，藥生請填藥師、護士請填護理師，若填寫「其他」將視為不需學分，課後也不予修改及補上傳，請於填答時自行留意。
(3)報名資料及上線資料皆須一致，請勿與他人共用連結或裝置進行觀看，若與他人共用裝置或是資料填寫錯誤，造成比對錯誤，導致學分無法上傳，事後將不予修正及補上傳學分，敬請留意。
上課證明
學員名單將於課後兩周內整理並上傳完成
(因填寫人數眾多將依序發送)
聯絡人資訊
